Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

The Lancet

Volumn 390, Issue 10106, 2017, Pages 1962-1971

  Giugliano, Robert P ^a   Pedersen, Terje R ^b   Park, Jeong Gun ^a   De Ferrari, Gaetano M ^c   Gaciong, Zbigniew A ^d   Ceska, Richard ^e   Toth, Kalman ^f   Gouni Berthold, Ioanna ^g   Lopez Miranda, Jose ^h   Schiele, François ⁱ   Mach, François ^j   Ott, Brian R ^k   Kanevsky, Estella ^a   Pineda, Armando Lira ^l   Somaratne, Ransi ^l   Wasserman, Scott M ^l   Keech, Anthony C ^m   Sever, Peter S ⁿ   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF PAVIA   (Italy)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF PÉCS   (Hungary)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITY OF CÓRDOBA   (Spain)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k BROWN UNIVERSITY   (United States)

^l AMGEN INC   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; EVOLOCUMAB; PLACEBO; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CATARACT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT WITHDRAWAL; UNSTABLE ANGINA PECTORIS; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECT; FEMALE; FOLLOW UP; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT SAFETY; RISK ASSESSMENT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT SAFETY; PROPROTEIN CONVERTASE 9; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85028372914     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32290-0     Document Type: Article

References (31)

1. Cholesterol Treatment Trialists Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
2. Grundy, SM, Cleeman, JI, Merz, CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004), 227–239.
3. Jacobson, TA, Ito, MK, Maki, KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 9 (2015), 129–169.
4. Jacobson, TA, Maki, KC, Orringer, CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol 9:suppl 6 (2015), S1–122.e121.
5. Catapano, AL, Graham, I, De Backer, G, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 37 (2016), 2999–3058.
6. Sabatine, MS, Giugliano, RP, Keech, AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
7. Giugliano, RP, Mach, F, Zavitz, K, et al. Evaluation of cognitive function in a randomized trial of evolocumab. N Engl J Med 377 (2017), 633–643.
8. Sabatine, MS, Giugliano, RP, Keech, A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J 173 (2016), 94–101.
9. Giugliano, RP, Mach, F, Zavitz, K, et al. Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy—a cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol 40 (2017), 59–65.
10. Farias, ST, Mungas, D, Reed, BR, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology 22 (2008), 531–544.
11. Friedewald, WT, Levy, RI, Fredrickson, DS, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972), 499–502.
12. Concato, J, Peduzzi, P, Holford, TR, Feinstein, AR, Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 48 (1995), 1495–1501.
13. Peduzzi, P, Concato, J, Feinstein, AR, Holford, TR, Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48 (1995), 1503–1510.
14. Peduzzi, P, Concato, J, Kemper, E, Holford, TR, Feinstein, AR, A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49 (1996), 1373–1379.
15. Rothman, KJ, No adjustments are needed for multiple comparisons. Epidemiology 1 (1990), 43–46.
16. Cannon, CP, Blazing, MA, Giugliano, RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
17. Giugliano, RP, Cannon, CP, Blazing, MA, et al. Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS. J Am Coll Cardiol, 65(suppl 10), 2015, A4.
18. Boekholdt, SM, Hovingh, GK, Mora, S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64 (2014), 485–494.
19. Wiviott, SD, Cannon, CP, Morrow, DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 46 (2005), 1411–1416.
20. Giugliano, RP, Wiviott, SD, Blazing, MA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol 2 (2017), 547–555.
21. Nicholls, SJ, Puri, R, Anderson, T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316 (2016), 2373–2384.
22. Ray, K, Ginsberg, H, Davidson, M, et al. Relationship between percentage reduction in low-density lipoprotein cholesterol levels and major atherosclerotic cardiovascular disease among patients treated with statins +/– alirocumab or ezetimibe in the phase 3 ODYSSEY trials. J Am Coll Cardiol, 67, 2016, 2082.
23. Pedersen, TR, Kjekshus, J, Berg, K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
24. Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998), 1349–1357.
25. Orringer, CE, Jacobson, TA, Saseen, JJ, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the National Lipid Association. J Clin Lipidol, 2017 published online May 19. DOI:10.1016/j.jacl.2017.05.001.
26. Maki, KC, Ridker, PM, Brown, WV, Grundy, SM, Sattar, N, The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol 8:suppl 3 (2014), S17–S29.
27. Bays, H, Cohen, DE, Chalasani, N, Harrison, SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 8:suppl 3 (2014), S47–S57.
28. Rosenson, RS, Baker, SK, Jacobson, TA, Kopecky, SL, Parker, BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8:suppl 3 (2014), S58–S71.
29. Lipinski, MJ, Benedetto, U, Escarcega, RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 37 (2016), 536–545.
30. Robinson, JG, Rosenson, RS, Farnier, M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol 69 (2017), 471–482.
31. Koren, MJ, Sabatine, MS, Giugliano, RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2 (2017), 598–607.